Inhibition of MET using specific inhibitors is also known to adversely affect NSCLC cell viability and is the basis for several ongoing clinical trials aimed at testing the efficacy of MET inhibitors in NSCLC and other cancers [26]. The gene discussed is MET; the disease is non-small cell lung carcinoma.